2009 Vol. 11, No. 2 353-356

## Toward the Total Synthesis of the Brasilinolides: Stereocontrolled Assembly of a C1—C19 Polyol Segment

lan Paterson,\*,† Friedrich A. Mühlthau,† Christopher J. Cordier,† Michael P. Housden,† Paul M. Burton,† and Olivier Loiseleur‡

University Chemical Laboratory, Lensfield Road, Cambridge CB2 1EW, U.K., and Syngenta Crop Protection AG, Schaffhauserstrasse, 4332 Stein, Switzerland

ip100@cam.ac.uk

Received November 6, 2008

## **ABSTRACT**

Two highly convergent syntheses of a fully protected C1—C19 polyol subunit of the brasilinolide family of immunosuppressive macrolides are described, exploiting boron-mediated 1,5-anti aldol couplings to form the C8—C9 and C13—C14 bonds.

The brasilinolides (1a–c, Scheme 1), first isolated in 1996 by Kobayashi and co-workers from the pathogenic actinomycete *Nocardia brasiliensis* IFM-0406, constitute a structurally unique family of bioactive 32-membered macrolides. Recently, the relative and absolute configuration was determined inter alia by controlled chemical degradation of brasilinolide C (1c) and detailed spectroscopic studies of the resulting fragments.<sup>2</sup>

Brasilinolide A (1a) exhibits immunosuppressive activity in the mouse mixed lymphocyte reaction, with an IC<sub>50</sub> of 0.625  $\mu$ g mL<sup>-1</sup>, and represents a recent addition to an important class of macrolactone immunosuppressants.<sup>3</sup> While

the immunosupressive effect is somewhat lower compared to cyclosporin A, rapamycin, and FK506, brasilinolide A stands out in showing no acute toxicity, even up to 500 mg kg<sup>-1</sup>. In addition, brasilinolide A is reported to show significant antifungal activity, and brasilinolide B (**1b**) is active against a range of fungi and bacteria. Altogether, their pronounced biological activities, along with the low toxicity profile and favorable physicochemical properties, support further evaluation of the brasilinolides. As part of studies toward a projected total synthesis of these highly oxygenated macrolides, we now report an expedient aldol-based construction of the fully protected C1–C19 polyol segment **2**, corresponding to the southern hemisphere region of the brasilinolides.

As outlined retrosynthetically in Scheme 1, simplification of brasilinolide A (1a) is achieved by the late-stage attachment of the polar C23-O-malonyl substituent and C37-O-glycosylation, following macrolactonization. An aldol coupling of methyl ketone fragment 3 with a suitable aldehyde derived from 2 is envisaged to control the C19 stereocenter and trigger hemiacetal formation with the C15 ketone,

<sup>†</sup> University of Cambridge.

<sup>‡</sup> Syngenta.

<sup>(1) (</sup>a) Shigemori, H.; Tanaka, Y.; Yazawa, K.; Mikami, Y.; Kobayashi, J. *Tetrahedron* **1996**, *52*, 9031. (b) Tanaka, Y.; Komaki, H.; Yazawa, K.; Mikami, Y.; Nemoto, A.; Tojyo, T.; Kadowaki, K.; Shigemori, H.; Kobayashi, J. *J. Antibiot.* **1997**, *50*, 1036. (c) Mikami, Y.; Komaki, H.; Imai, T.; Yazawa, K.; Nemoto, A.; Tanaka, Y.; Gräfe, U. *J. Antibiot.* **2000**, *53*, 70.

<sup>(2)</sup> Komatsu, K.; Tsuda, M.; Tanaka, Y.; Mikami, Y.; Kobayashi, J. J. Org. Chem. **2004**, 69, 1535.

<sup>(3)</sup> For a review of the chemistry and biology of immunosuppressive natural products, see: Mann, J. *Nat. Prod. Rep.* **2001**, *18*, 417.

Scheme 1. Retrosynthetic Analysis of the Brasilinolides

leading to the full C1-C38 seco-acid precursor. Further analysis of the pivotal C1-C19 segment 2 suggests that aldol-type bond scissions might be made productively at C8-C9 and C13-C14. This highly convergent strategy relies on exploiting the two 1,5-anti diol relationships highlighted in segment 2 using our boron aldol methodology.<sup>4,5</sup> Thus, the C9 center in 2 will be configured using the C5 center by the addition of a boron enolate derived from  $\beta$ -alkoxy ketone 4 to a suitable aldehyde, while C13 might be set in a similar manner, exploiting the anticipated 1,5-anti stereoinduction from C17 in methyl ketone 5. Given the protecting group requirements for 1,5-anti aldol reactions, the methyl ketones 4 and 5 have PMB ethers at C5 and C17, with aldehydes 6 and 7 selected as two possible connecting building blocks. In the two syntheses of the C1-C19 segment 2 described herein, aldehydes 6 and 7 play the role of a bifunctional C9-C13 central unit.

Synthesis of the C1–C8 ketone **4** commenced with the epoxide **8** (Scheme 2), prepared in two steps from (*S*)-(+)-epichlorohydrin.<sup>6</sup> Epoxide opening proceeded at ambient temperature in DMSO using lithium acetylide ethylene diamine complex. The resulting alcohol was transformed into the PMB ether **9**, and hydration of the alkyne proceeded smoothly using PPTS (1.5 equiv) and Hg(OAc)<sub>2</sub> (0.3 equiv) in wet acetone.<sup>7</sup> Olefin cross-metathesis with methyl acrylate

(Grubbs II, 1 mol %)<sup>8</sup> then afforded the enantiopure ketone **4** in four steps and 52% yield from **8**.

Synthesis of the C14–C19 ketone **5** (Scheme 2) relied on Sharpless asymmetric dihydroxylation and began with the silyl ether **10**, which was converted directly into the enone **11** using a method described by Hon (76%, >95:5 E/Z). An optimized Sharpless dihydroxylation of **11**, utilizing the (DHQ)<sub>2</sub>AQN ligand, provided the required  $\alpha,\beta$ -dihydroxy ketone efficiently (84%, 97% ee). Conversion into the bis-PMB ether (PMBTCA, cat. Ph<sub>3</sub>CBF<sub>4</sub>)<sup>12</sup> then gave the methyl ketone **5** in three steps and 49% overall yield from the silyl ether **10**.

Org. Lett., Vol. 11, No. 2, 2009

<sup>(4) (</sup>a) Paterson, I.; Gibson, K. R.; Oballa, R. M. *Tetrahedron Lett.* **1996**, *37*, 8585. (b) Paterson, I.; Collett, L. A. *Tetrahedron Lett.* **2001**, *42*, 1187.

<sup>(5)</sup> For related studies from the Evans group, see: (a) Evans, D. A.; Coleman, P. J.; Côté, B. *J. Org. Chem.* **1997**, *62*, 788. (b) Evans, D. A.; Côté, B.; Coleman, P. J.; Connell, B. T. *J. Am. Chem. Soc.* **2003**, *125*, 10893.

<sup>(6) (</sup>a) Burova, S. A.; McDonald, F. E. *J. Am. Chem. Soc.* **2004**, *126*, 2495. (b) De Camp Schuda, A.; Mazzocchi, P. H.; Fritz, G.; Morgan, T. *Synthesis* **1986**, 309.

<sup>(7)</sup> Paterson, I.; Tudge, M. Tetrahedron 2003, 59, 6833.

<sup>(8)</sup> Chatterjee, A. K.; Choi, T.-L.; Sanders, D. P.; Grubbs, R. H. J. Am. Chem. Soc. 2003, 125, 11360.

<sup>(9)</sup> Hon, Y.-S.; Lu, L.; Chang, R.-C.; Lin, S.-W.; Sun, P.-P.; Lee, C.-F. *Tetrahedron* **2000**, *56*, 9269.

With the two methyl ketones 4 and 5 required for the aldol fragment assembly in hand, the synthesis of the prospective aldehyde partners 6 and 7 was now addressed (Scheme 3).

Beginning with the propionamide 12, a Myers alkylation<sup>13</sup> was used to install the C12 stereocenter providing 13 essentially as a single diastereomer (98% yield). Reductive cleavage of the auxiliary using LDA·BH<sub>3</sub> complex and Swern oxidation of the resulting alcohol provided the C13 aldehyde 6 in 88% yield and excellent enantiopurity (97% ee). Preparation of the C9 aldehyde 7 utilized an auxiliary-controlled Michael addition developed by Evans. <sup>14</sup> Formation of the titanium enolate of 14 and addition of acrylonitrile provided the nitrile 15 (83%, 96:4 dr). The auxiliary was subsequently cleaved using NaBH<sub>4</sub> and the resulting alcohol was converted into its TBS ether. Reduction of the nitrile using DIBAL-H then gave the aldehyde 7 in four steps and 48% yield from 14.

With all four building blocks **4**–**7** prepared, their boronmediated aldol coupling was explored, relying on 1,5-*anti* induction from the C5 and C17 stereocenters. In the initial route examined (Scheme 4), the C8–C9 bond was formed before the C13–C14 bond. Based on our standard protocol,<sup>4</sup> the methyl ketone **4** was enolized using c-Hex<sub>2</sub>BCl and Et<sub>3</sub>N at 0 °C. Addition of aldehyde **7** at -78 °C then gave the desired 1,5-*anti* adduct **16** in 88% yield and with >95:5 dr.

## Scheme 4

Hydroxyl-directed reduction of the C7 ketone in **16** using Me<sub>4</sub>NBH(OAc)<sub>3</sub> afforded the 1,3-*anti* diol **17** cleanly (>95:5 dr). Next, the diol **17** was converted into the di-*tert*-butylsilylene derivative **18**, followed by cleavage of the TBS ether with CSA/MeOH and Dess—Martin oxidation to give the aldehyde **19**.

The pivotal aldol coupling between **5** and **19** now depended on the extension of 1,5-*anti* boron aldol methodology to include enolates such as **20** that have an alkoxy stereocenter at the  $\alpha$ -position as well as the  $\beta$ -position. DFT calculations predicted that these aldol reactions will proceed preferentially through *TS-I*, where  $\pi$ -facial discrimination

Org. Lett., Vol. 11, No. 2, 2009

<sup>(10)</sup> Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. *Chem. Rev.* **1994**, *94*, 2483.

<sup>(11)</sup> See the Supporting Information for details.

<sup>(12) (</sup>a) Ireland, R. E.; Liu, J.; Roper, T. D. *Tetrahedron* **1997**, *53*, 13221. (b) Paterson, I.; Coster, M. J.; Chen, D.Y.-K.; Acena, J. L.; Bach, J.; Keown, L.; Trieselmann, T. *Org. Biomol. Chem.* **2005**, *3*, 2420.

<sup>(13)</sup> Myers, A. G.; Yang, B. H.; Chen, H.; McKinstry, L.; Kopecky, D. J.; Gleason, J. L. J. Am. Chem. Soc. 1997, 119, 6496.

<sup>(14) (</sup>a) Evans, D. A.; Bilodeau, M. T.; Somers, T. C.; Clardy, J.; Cherry, D.; Kato, Y. *J. Org. Chem.* **1991**, *56*, 5750. (b) Yokoshima, S.; Ueda, T.; Kobayashi, S.; Sato, A.; Kuboyama, T.; Tokuyama, H.; Fukuyama, T. *J. Am. Chem. Soc.* **2002**, *124*, 2137.


<sup>(15)</sup> Evans, D. A.; Chapman, K. T.; Carreira, E. M. J. Am. Chem. Soc. **1988**, 110, 3560.

<sup>(16)</sup> The configurations of the stereocenters at C7 and C9 were confirmed by (i) conversion of **17** into the 7,9-anti acetonide and <sup>13</sup>C NMR analysis using Rychnovsky's method and (ii) treatment of **17** with DDQ to generate the corresponding 5,7-syn PMP acetal and NOE analysis. Rychnovsky, S. D.; Rogers, B. N.; Richardson, T. I. Acc. Chem. Res. **1998**, *31*, 9.

to favor adduct **21** is controlled by a stabilizing formyl H-bond involving only the PMB ether oxygen at the  $\beta$ -center and minimization of steric interactions. <sup>17</sup> Initially, the inherent diastereoselectivity of the boron enolate **20** derived from ketone **5** was determined by its addition to isobutyral-dehyde, leading to formation of the 1,5-anti adduct **22** with 89:11 dr. <sup>18</sup> Having established that the expected stereoinduction was operating, the C13–C14 aldol coupling between enolate **20** and aldehyde **19** was performed to give the required adduct **23** selectively (70%, 87:13 dr). Silylation of alcohol **23** then afforded the C1–C19 segment **2** with a longest linear sequence of 11 steps from **8** and 11.5% overall yield.

In an alternative assembly of the southern hemisphere region of the brasilinolides, the C13-C14 aldol coupling step was performed first (Scheme 5). Under optimized conditions, the methyl ketone 5 was enolized using Bu<sub>2</sub>BOTf and *i*-Pr<sub>2</sub>NEt at −78 °C. Addition of aldehyde **6** at −98 °C provided the desired 1,5-anti adduct 24 with excellent diastereoselectivity (81%, 96:4 dr). Following TBS ether formation to give 25, the C9 aldehyde was unmasked by controlled ozonolysis<sup>19</sup> to give **26** (95%). A C8–C9 aldol coupling was then performed with the boron enolate 27 derived from 4 using the previously developed conditions, giving the 1,5-anti adduct 28 with equally high diastereoselectivity (81%, >95:5 dr). The sequence was concluded with an Evans-Saksena reduction of 28 to install the C7 stereocenter, followed by protection of the resulting 1,3-anti diol to give 2.20 This second route to the C1-C19 segment 2 has nine steps in the longest linear sequence starting from 10 and proceeded in an improved overall yield of 17.4%.

In summary, we have completed the stereocontrolled synthesis of the fully protected C1-C19 polyol segment **2** of the brasilinolides using two highly convergent routes. Efficient fragment couplings were achieved using boron-mediated 1,5-anti aldol reactions. Ongoing work into the assembly of the northern hemisphere **3** (Scheme 1) should



further advance the total synthesis of this novel family of immunosuppressive macrolides.

**Acknowledgment.** We thank the EPSRC (EP/F025734/1) and Syngenta for support and the Deutsche Akademie der Naturforscher Leopoldina (F.A.M.; BMBF-LPD 9901/8-148) and the Herchel Smith Postdoctoral Fellowships Fund at Cambridge (C.J.C.) for additional funding.

**Supporting Information Available:** Experimental procedures and spectroscopic data for new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

OL802562B

356 Org. Lett., Vol. 11, No. 2, 2009

<sup>(17)</sup> We thank Dr. Rob Paton for carrying out transition state calculations for  $R^1$  = Me and  $R^2$  = (*E*)-CH=CHMe, where *TS-I* leading to adduct **21** was preferred. Paton, R. S.; Goodman, J. M. *J. Org. Chem.* **2008**, *73*, 1253.

<sup>(18)</sup> The configuration was determined by use of the advanced Mosher method: Ohtani, I.; Kasumi, T.; Kashman, Y.; Kakisawa, H. *J. Am. Chem. Soc.* **1991**, *113*, 4092.

<sup>(19)</sup> The use of an indicator (Sudan red 7B) was crucial to prevent oxidation of the PMB ethers. Veysoglu, T.; Mitscher, L. A.; Swayze, J. K. Synthesis 1980, 807.

<sup>(20)</sup> The spectroscopic data of 2 matched that of material prepared via the route described in Scheme 4.